NCT05808153 · RECRUITING

Innovative Imaging and Cognitive BIOmarkers to Predict Huntington's Disease Progression

This trial is studying new brain imaging techniques and cognitive tests to better track Huntington's disease progression. It uses a radiotracer injection to get detailed brain scans, alongside other biological and cognitive measures. Researchers want to find more sensitive markers for the disease before and after symptoms appear. This is a Phase NA observational study — it is gathering data to improve future research tools, not testing a treatment.

Eligibility criteria

Inclusion Criteria:
* For all participants:
* Age ≥18 years and ≤65 years
* Information and collection of written consent
* Affiliation with a social security plan, beneficiary or beneficiary's right
* Healthy controls
* UHDRS functional score TFC = 13
* Motor UHDRS score TMS \< 6 With no known genetic disease and no direct relationship to an HD patient or family ancestors carrying the HD mutation (or knowing their genetic status with CAG \< 36).
* Manifest carriers
* Number of GACs ≥ 40
* CAP score ≥ 250
* 10 ≤ TFC ≤ 13
* TMS >5 if TFC=13
* Diagnostic confidence level =4
* Age of onset of disease > 20 years
* Patients physically able to sign consent
* Premanifest carriers
* Number of GACs ≥ 40
* CAP score ≥250
* CFT = 13
* TMS \< 6
* Patients physically able to sign consent
Exclusion Criteria:
* Participant under guardianship or curatorship
* Neurological or psychiatric disorder unrelated to HD
* Intercurrent illness that may impact participant's performance
* Chronic progressive neurological disease
* Claustrophobia
* Brain injury unrelated to HD
* Pacemaker, intracorporeal metal, intracerebral clip, any metallic foreign body: implantable cardiac electronic device such as pacemakers, implantable cardioverter defibrillators etc., metallic intraocular foreign bodies, implantable neurostimulation systems, cochlear implants/ear implants, drug infusion pumps (insulin administration, analgesic drugs), or chemotherapy pumps): if possible, the patient should remove the device.
* Catheters with metal components (Swan-Ganz catheter), metal fragments such as bullets, shotgun pellets and metal shrapnel, cerebral artery aneurysm clips, magnetic dental implants, tissue expander, artificial limb, hearing aid, piercing such as pacemaker,
* Known hypersensitivity to the radiopharmaceutical preparation (excipients in the radiopharmaceutical preparation)
* Pregnant or breastfeeding woman
* Person under state medical aid
* Person deprived of liberty
* Person participating or having participated in an interventional study for less than 3 months or without time limit in a trial of neural transplants or gene therapy.
* Person participating or having participated in a research protocol with a radiopharmaceutical injection for less than 12 months.
* Neurological or psychiatric disorder unrelated to HD
* Intercurrent disease that may impact participant's performance
* Chronic progressive neurological disease
* Claustrophobia
* Brain injury unrelated to HD
* Pacemaker, intracorporeal metal, intracerebral clip
* Pregnant, breastfeeding or wanting to procreate during participation in the study.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2024-05-07

View full record on ClinicalTrials.gov

All APOE4 clinical trials